secwatch.observer — SEC 8-K summary
======================================

Issuer:     SCYNEXIS INC (SCYX)
CIK:        0001178253
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001193125-26-133250
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SCYNEXIS acquires PXL-770 (SCY-770) from Poxel for $8M upfront, up to $188M total
--------------------------------------------------------------------------------

- Asset includes direct AMPK activator PXL-770, now SCY-770, for ADPKD, with Orphan Drug Designation from FDA.
- Upfront payment of $8M; potential development milestones up to $8M and commercial milestones up to $180M.
- Phase 2 proof-of-concept study in ADPKD expected to start Q4 2026; early efficacy readout anticipated H2 2027.
- SCY-770 has been evaluated in eight clinical trials with a favorable safety profile and targets underlying ADPKD drivers.
- SCYNEXIS plans to host a conference call on March 31, 2026 at 8:30 AM ET to discuss the acquisition and corporate update.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178253/000119312526133250/0001193125-26-133250-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178253/000119312526133250/d118823d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-133250

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer